Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21703
Title: Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
Austin Authors: Gunjur, Ashray ;Klein, Oliver ;Kee, Damien ;Cebon, Jonathan S 
Affiliation: Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, University of Melbourne, Melbourne, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Issue Date: 5-Sep-2019
metadata.dc.date: 2019-09-05
Publication information: Journal for Immunotherapy of Cancer 2019; 7(1): 241
Abstract: Autoimmune polyendocrine syndrome type II (APS-2) is a rare constellation of autoimmune hypoadrenalism, thyroid dysfunction and/or type 1 diabetes (T1DM), usually occurring in the 3rd or 4th decades and associated with a human leukocyte antigen (HLA) DR3 or DR4 serotype. We detail the first report of an elderly woman developing the full triad of APS-2 shortly after commencing anti-programmed cell death protein 1 (anti-PD1) immune checkpoint inhibition for unresectable melanoma and review the literature for similar presentations secondary to anti-PD1 axis therapy. A 78-year-old female with advanced unresectable BRAF wild-type melanoma was treated with pembrolizumab (2 mg/kg 3-weekly). Three weeks following the first dose she developed fulminant autoimmune diabetes, with an initially low C-peptide denoting rapid destruction of ß-islet cells. Following stabilisation of her diabetes, two further doses of pembrolizumab was administered. She then represented with symptomatic hypoadrenalism and hypothyroidism, consistent with APS-2. Her HLA class II genotype was HLA-DRB1*04.16 (DR4 serotype), a recognised association with this syndrome. Her melanoma responded rapidly to anti-PD1 therapy, and a complete response (CR) was attained after four doses of pembrolizumab. Treatment was discontinued and her CR is ongoing. This is the first report of the full triad of APS-2 developing in a genetically susceptible individual at the age of 78 after treatment with an anti-PD1 agent. Although scarcely reported, a literature review of similar reports seems to indicate a predilection for this syndrome in patients with HLA-DR4 serotypes. HLA Class II typing is not routinely recommended, but may provide useful predictive information for patients at risk of poly-endocrinopathy even in patients without a relevant personal or family history. Additional studies are required to determine if such testing would be useful and/or cost effective.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21703
DOI: 10.1186/s40425-019-0713-y
ORCID: 0000-0001-9713-1872
0000-0002-3898-950X
PubMed URL: 31488221
Type: Journal Article
Subjects: Diabetes mellitus
Hypoadrenalism
Hypothyroidism
Immune checkpoint inhibitor
PD1 inhibitor
Pembrolizumab
Poly-endocrinopathy
Appears in Collections:Journal articles

Show full item record

Page view(s)

16
checked on Dec 8, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.